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Standard treatment for operable patients with single peripheral lung metastases is
metastasectomy. We report mature CyberKnife outcomes for high-risk surgical patients
with biopsy proven single peripheral lung metastases. Twenty-four patients (median age
73 years) with a mean maximum tumor diameter of 2.5 cm (range, 0.8–4.5 cm) were treated
over a 6-year period extending from September 2004 to September 2010 and followed for
a minimum of 1 year or until death. A mean dose of 52 Gy (range, 45–60 Gy) was delivered
to the prescription isodose line in three fractions over a 3–11 day period (mean, 7 days).
At a median follow-up of 20 months, the 2-year Kaplan–Meier local control and overall sur-
vival rates were 87 and 50%, respectively. CyberKnife with fiducial tracking is an effective
treatment for high-risk surgical patients with single small peripheral lung metastases. Tri-
als comparing CyberKnife with metastasectomy for operable patients are necessary to
confirm equivalence.
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INTRODUCTION
Historically, metastatic tumors have been treated with palliative
systemic and local therapies. Radiation therapy was delivered
selectively in moderate doses to alleviate tumor related symp-
toms. This approach contrasts with current innovative treatment
paradigms, which often emphasize combination therapies, where
surgery and radiation therapy are designed to eradicate gross
tumor and systemic therapy to eliminate micrometastases.
The lung represents a common site of metastatic disease
(Pastorino, 1997). Frequently, it is the only organ involved and
tumors are limited in number (Casiraghi et al., 2011). In this
setting, chemotherapy and metastasectomy have been combined
to enhance overall survival. The International Registry of Lung
Metastases (1997) reported an increase in 5 year survival following
complete metastasectomy, 36 vs. 13% (1997). This result suggests
that the complete eradication of gross lung metastases enhances
overall survival. Recently, the European Institute of Oncology
reported 2- and 5-year overall survival rates of 74 and 46%,
respectively, with modern patient selection, contemporary sys-
temic therapy, and complete metastasectomy (Casiraghi et al.,
2011).
For high-risk surgical patients and those electing not to pur-
sue surgery, stereotactic body radiotherapy (SBRT) can reliably
eradicate lung metastases (Siva et al., 2010). SBRT trials, utiliz-
ing adequate tumor doses and standard margins (5 mm in the
axial plane and 10 mm in the cranial-caudal plane), have consis-
tently reported local control rates at 2 years of approximately 90%
(Siva et al., 2010). Preliminary data suggests that CyberKnife
(Accuray Incorporated, Sunnyvale, CA, USA) treatment with fidu-
cial tracking reliably eradicates pulmonary metastases with addi-
tional lung tissue sparing (Collins et al., 2007). Continuous track-
ing of tumor motion due to respiration and highly accurate beam
alignment throughout treatment with the CyberKnife facilitates
the accurate delivery of dose distributions with tighter margins
on the gross tumor volume (GTV) than historically feasible with
conventional SBRT (Hoogeman et al., 2009).
We began treating high-risk surgical patients with single lung
metastases in mid 2004 using the CyberKnife frameless robotic
radiosurgery system with Synchrony tumor motion tracking
(Collins et al., 2007). The goal of this treatment was to maintain
the impressive local control rates of conventional SBRT while fur-
ther decreasing radiation-induced lung damage with tight 5 mm
margins. We report local control and overall survival rates for
24 consecutively treated, patients at high-risk for surgical man-
agement with single peripheral lung metastases treated using the
CyberKnife system with fiducial tracking.
MATERIALS AND METHODS
ELIGIBILITY
The Medstar Health Research Institute-Georgetown University
Oncology institutional review board approved this retrospective
analysis of a prospectively collected database. All participants
provided informed written consent. The Georgetown Univer-
sity Hospital multidisciplinary thoracic oncology team evaluated
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patients. Prior to treatment, CT imaging of the chest, abdomen,
and pelvis with IV contrast, PET imaging, and routine pulmonary
function tests (PFTs) were completed when feasible. High-risk sur-
gical patients with pathologically confirmed single peripheral lung
metastases measuring 5 cm or less in maximum diameter were
considered for treatment. High-risk was defined by the presence
of any of the following: a post-bronchodilator percent predicted
forced expiratory volume in 1 s (FEV1) of less than 50%, a carbon
monoxide diffusing capacity (DLCO) of less than 50%, age greater
than 75, prior lobectomy, or severe comorbid medical conditions
with poor performance status. A metastasis was considered a single
peripheral metastasis if there was no evidence of additional gross
metastases at the time of treatment per PET/CT imaging and the
lesion could be treated while respecting critical central structure
radiation dose limits (Table 1). Finally, candidates were excluded
from treatment if fiducials could not be safely placed for tumor
tracking.
FIDUCIAL PLACEMENT
Under conscious sedation and with local anesthesia, three to five
gold fiducials measuring 0.8–1 mm in diameter and 3–7 mm in
length (Item 351-1 Best Medical International, Inc., Springfield,
VA, USA) were placed for tumor tracking. CT-guidance was uti-
lized to ensure adequate spacing (1–2 cm) and proximity to lesions
as previously described (Yousefi et al., 2007).
TREATMENT PLANNING
Fine-cut (1.25 mm) treatment planning CTs were routinely
obtained 7–10 days after fiducial placement during a full inhala-
tion breath-hold. GTV were contoured utilizing lung windows.
The GTV margin was expanded 5 mm to establish the planning
treatment volume (PTV). All critical central thoracic structures
(Table 1) and the lungs were contoured to ensure that inci-
dental radiation delivered to those structures was limited. The
dose to the chest wall and skin was not limited. A treatment
plan was generated using the CyberKnife non-isocentric, inverse-
planning ray-tracing algorithm with tissue density heterogeneity
corrections for lung. Lower doses within the institutions accepted
range of 45–60 Gy in three fractions were prescribed at the last
author’s discretion when concerns about adjacent critical struc-
tures arose (Table 1) and/or when patients were felt to have severe
pulmonary dysfunction. The radiation was delivered to an iso-
dose line that covered at least 95% of the PTV. The percentage of
the total lung volume receiving 15 Gy or more (V15) was limited
to 15%.
Table 1 | Critical central structure radiation point dose limits.
Adjacent structure Maximum dose limit (total for 3 fractions; Gy)
Spinal cord 18
Esophagus 27
Heart 30
Main bronchus 30
Trachea 30
Great vessels 40
TREATMENT DELIVERY
Patients were treated according to the Georgetown University Hos-
pital small peripheral pulmonary nodule protocol as previously
described (Collins et al., 2007). Briefly, patients were positioned
supine and unrestrained on the treatment table with their arms
at their sides, and they were placed in a tightly fitted vest with
three red light emitting diodes (LEDs) on the anterior portion. The
LEDs were positioned over the approximate maximum respiratory
excursion point of the lower chest and upper abdomen. They were
adjusted to project to a camera array within the treatment room.
The automated patient positioning system was utilized to adjust
the treatment table, and orthogonal X-ray images were employed
to register the implanted fiducials. These images were obtained by
ceiling mounted X-ray sources and corresponding floor mounted
amorphous silicon image detectors.
As described in detail elsewhere (Kilby et al., 2010), immedi-
ately prior to starting treatment, Synchrony creates an adaptive
correlation model between the fiducial positions as imaged by
the X-ray targeting system and the LEDs as imaged by the by
the camera array. The X-ray targeting system reacquired fiducials
periodically throughout therapy, while the LEDs were continu-
ously tracked. The linear accelerator was moved by the robotic
arm which adjusted position in real-time to maintain alignment
with the target. The patient’s breathing was uninhibited during
this process. Fiducials were imaged prior to every third beam in
order to update the correlation model and to verify treatment
positioning. If the correlation model error exceeded 3 mm or if
fiducials were misidentified, the treatment was discontinued, and
the model was recreated.
FOLLOW-UP STUDIES
Examination and CT imaging were routinely performed at
3 month follow-up intervals. PET/CT imaging was completed
selectively to evaluate suspicious CT changes. Local recurrence
was defined as progression within 2 cm of the tracked fiducials
per PET/CT imaging as previously described (Vahdat et al., 2010).
Other failures were considered distant. Upon failure, biopsy was
required to confirm local progression.
STATISTICAL ANALYSIS
Data was analyzed and graphs were prepared with the SPSS 16.02
statistical package (IBM Corporation, Armonk, NY, USA). The
follow-up duration was defined as the time from the date of com-
pletion of CyberKnife treatment to the last date of follow-up or
date of death. Actuarial local control and overall survival were
calculated using the Kaplan–Meier method.
RESULTS
PATIENT AND TUMOR CHARACTERISTICS
Twenty-four patients (15 men and 9 women) with single periph-
eral lung metastases and an Eastern Cooperative Oncology Group
(ECOG) performance status of two or less were treated over a
6-year period extending from September 2004 to September 2010
(Table 2). The mean maximum tumor diameter was 2.5 cm (range,
0.8–4.5 cm). Primaries included lung adenocarcinoma (n= 7),
lung squamous cell carcinoma (n= 7), esophagus (n= 2), uterus
(n= 2), ovary (n= 1), small bowel (n= 1), pancreas (n= 1), blad-
der (n= 1), renal (n= 1), and skin (n= 1). Ninety-two percent
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Table 2 | Patient and tumor characteristics.
FEV1 (L)
Mean 1.67
Range 0.54–2.82
PREDICTED FEV1 (%)
Mean 66
Range 28–121
DLCO (mL/min/mmHg)
Mean 13.0
Range 4.5–22.1
PREDICTED DLCO (%)
Mean 62
Range 20–96
ECOG
Median 1
Range 0–2
AGE (YEARS)
Median 73
Range 53–85
SEX (%)
Male 63
Female 37
RACE (%)
Caucasian 79
African 17
Asian 4
Smoker (%) 92
MAXIMUM DIAMETER (cm)
Mean 2.5
Median 2.5
Range 0.8–4.5
of the patients were smokers; the mean post-bronchodilator per-
cent predicted FEV1 was 66% (range, 28–121%). Half of the
patients had prior lobectomy; two thirds of the patients were not
chemotherapy candidates.
TREATMENT
Treatment plans were composed of a mean of 179 pencil beams
(Table 3). A mean dose of 52 Gy (range, 45–60 Gy) was delivered
to the prescription isodose line in three 1–2 h treatments over a
3–11 day period (mean, 7 days).
COMPLICATIONS
Four patients developed pneumothorax requiring tube thora-
costomy following biopsy and fiducial placement. Subsequently,
all patients completed treatment without interruption. Imme-
diately following treatment, acute toxicity consisting of mild
brief fatigue was reported in the majority of patients. Dur-
ing the first year transient mild-to-moderate chest wall dis-
comfort, typically lasting several weeks, developed in seven of
nine patients for lesions within 5 mm of the pleura. Skin tox-
icity, chronic chest wall pain, rib fracture, and symptomatic
radiation pneumonitis (≥Grade II) were not observed in this
cohort.
Table 3 |Treatment characteristics.
Mean (range)
Prescribed dose (Gy) in 3 treatments 52 (45–60)
Prescription isodose line (%) 80 (75–85)
Number of beams per treatment 179 (79–279)
Treatment course (days) 7 (3–11)
DISEASE SPREAD AND SURVIVAL
At a median follow-up of 20 months (range, 6–80 months), 2
local failures at 11 and 18 months have been confirmed. Nineteen
patients died during follow-up; 11 patient deaths were attributed
to additional metastases and eight were attributed to cardiopul-
monary failure. No deaths were attributed to local failure or treat-
ment. The 2-year Kaplan–Meier local control and overall survival
estimates were 87 and 50%, respectively (Figures 1 and 2).
DISCUSSION
In mid 2004, we initiated CyberKnife treatment of high-risk surgi-
cal patients with single small (<5 cm) peripheral lung metastases
(Collins et al., 2007). Twenty-four patients were treated in 6 years
and followed for a minimum of 1 year or until death. Continuous
tracking of respiratory tumor motion and highly accurate beam
alignment throughout treatment with the CyberKnife prompted
us to deliver dose distributions with tighter (5 mm) margins on
the GTV than historically feasible. At a median follow-up of
20 months, the 2-year Kaplan–Meier estimated local control rate is
87%. Therefore, we conclude that CyberKnife with tumor tracking
is a highly effective treatment for small peripheral lung metastases.
Metastasectomy and CyberKnife are reasonable treatment options
for high-risk surgical patients with these tumors.
Some limitations concerning our conclusions exist. PET/CT
imaging surveillance promptly identifies local recurrence follow-
ing metastasectomy. However, high peritumoral lung doses often
result in focal radiation-induced pneumonitis and fibrosis, ham-
pering PET/CT recurrence assessment following irradiation (Vah-
dat et al., 2010). Routine biopsy was not completed in our cohort
given the uncertain clinical significance of early transient eleva-
tions in tumor maximum standardized uptake value (SUVmax)
following radiation treatment and the risk associated with biopsy
in these high-risk surgical patients with limited salvage treatment
options. As a result, confirmation of radiographic impressions was
limited to biopsy in two patients following a persistent increase in
tumor SUVmax; biopsies were not taken to confirm the absence of
disease in cases in which tumor SUVmax remained low or returned
to the normal range following transient elevations. Therefore, it
is possible that the actual 2-year local control rate is less than the
reported 87% rate.
Overall survival was vastly inferior in this group of patients
when compared to published metastasectomy cohorts (Pastorino,
1997; Casiraghi et al., 2011). At a median follow-up of 20 months,
the 2-year Kaplan–Meier overall survival estimate is merely 50%.
We limited our study to single pulmonary metastases in an effort
to simplify the analysis and to prevent inflated local control rates
resulting from poor overall survival. Inadvertently, we treated a
poor prognosis group of patients primarily consisting of elderly
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FIGURE 1 | Kaplan–Meier local control plot.
male former heavy smokers with chronic obstructive pulmonary
disease (COPD) and non-small cell lung cancer (NSCLC). These
patients were also generally considered poor candidates for
chemotherapy. Despite the limitations of this study, we continue
to treat selected consenting high-risk surgical patients with sin-
gle small peripheral pulmonary metastases using CyberKnife. The
encouraging local control rates in this study adequately support
this practice for this frail patient population with predictably short
survival (Siva et al., 2010).
Critical central structure toxicity was not observed in this trial.
It is likely that toxicity was absent because we strictly adhered
to conservative maximum point dose limits for critical central
structures (Table 1). However, transient mild-to-moderate chest
wall pain typically lasting several weeks was seen following treat-
ment in the majority of patients with lesions within 5 mm of
the pleura. These patients were treated conservatively with non-
steroidal anti-inflammatory medications or opioid analgesic com-
binations. Observations of such chest wall pain are common in
lung SBRT with many studies reporting even greater amounts
of significant toxicity. Indeed, rib fractures following SBRT have
been reported at rates ranging from 16–23% (Voroney et al., 2009;
Dunlap et al., 2010; Nambu et al., 2011). Our treatment main-
tains a mean dose of 52 Gy which is less than standard treatment.
FIGURE 2 | Kaplan–Meier overall survival plot.
Thus, while it is tempting to further limit the dose delivered to
the chest wall in these patients, this would likely result in addi-
tional local failures and is not recommended at this time given
the nominal toxicity observed using our treatment approach to
date
Finally, the current CyberKnife treatment approach requires the
implantation of fiducials to permit tumor tracking. The procedure
can result in pneumothorax, sometimes requiring tube thoracos-
tomy, and a brief hospital stay (Collins et al., 2007). Our institution
has developed a technique for placing fiducials via bronchoscopy
which significantly reduces the risk of pneumothorax (Reichner
et al., 2005). In our opinion, the unparalleled accuracy of fidu-
cial tracking justifies this placement risk, which in our institution
is routinely completed during required tissue confirmation of
malignancy prior to radiation treatment.
CONCLUSION
CyberKnife is an effective treatment for single small periph-
eral lung metastases. Our experience suggests that this therapy
will result in durable local control and is appropriate for high-
risk surgical patients. Clinical trials comparing CyberKnife with
metastasectomy for operable patients are necessary to confirm
equivalence.
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